Biotech week ahead, Oct. 7

Notwithstanding the ESMO conference generating some huge moves in some stocks, last week turned out to be a muted one for biotechs.
A few FDA approvals came through, with Puma Biotechnology Inc PBYI 2.15% getting a label expansion for its breast cancer drug Nerlynx and Novartis AG NVS 0.82%‘s Entresto, a combo therapy, given the go ahead for pediatric heart failure.

Here are the key biotech catalysts for the unfolding week.

Conferences

• European Huntington Association Conference: Oct. 4–6 in Bucharest, Romania
• Experts Gather on Cardiovascular Disorders and Cardiology Research: Oct. 7-8 in Paris, France
• 5th Annual Congress on Infectious Diseases: Oct. 7-8 in Frankfurt, Germany
• 9th International Conference on Neurological Disorders & Stroke: Oct. 7-8 in Dublin, Ireland
• Chardan 3rd Annual Genetic Medicines Conference: Oct. 7-8 in New York City
• Jefferies Gene Therapy/Editing Summit: Oct. 8 in New York City
• 37th World Cancer Conference: Oct. 9-10 in Dublin
• 28th European Academy of Dermatology and Venereology, or EADV, Congress: Oct. 9-13, in Madrid, Spain
• Ophthalmology Innovation Summit: Oct. 10 in San Francisco, California
• American Academy of Ophthalmology, or AAO: Oct. 12-15, in San Francisco

PDUFA Dates

The FDA is scheduled to rule on Pfenex Inc PFNX 6.05%‘s PF708, a therapeutic equivalent of Eli Lilly And Co LLY 0.81%‘s Forteo, which was approved in 2002 to treat osteoporosis in men and menopausal women, who are at high risk of having a fracture. The PDUFA date is set for Monday.
The regulatory body will issue its verdict Tuesday on Clinuvel Pharmaceuticals Ltd CLVLY 7.12%‘s NDA for Scenesse, which is being evaluated as a preventative treatment for phototoxicity and anaphylactoid reactions in adult patients with erythropoietic protoporphyria.

Clinical Trial Readouts

28th EADV Congress Presentations

Akari Therapeutics PLC AKTX – Additional Phase 2 data for Coversin in bullous pemphigoid (Thursday)
Concert Pharmaceuticals Inc CNCE 0.86% – Phase 2 data for CTP-543 in alopecia areata (Saturday)

AAO 2019 Presentations

Adverum Biotechnologies Inc ADVM 0.54% – Additional Phase 1 data for ADVM-022 in wet age-related macular degeneration Friday)
Regenxbio Inc RGNX 1.4% – Phase 1/2a data for RGX-314 in wet age-related macular degeneration (Friday)

IPOs

BioNTech, a German biotech developing individualized monotherapies for cancer, is planning a 13.2-million share IPO, which is estimated to be priced between $18 and $20. The company proposes to list shares on the Nasdaq under the ticker symbol “BNTX.”
Vir Biotechnology, a biotech developing immunologic therapies for infectious diseases, is seeking to list shares on the Nasdaq through an IPO of 7.14 million shares in the price range of $20 to $22 per share. Shares will be listed under the ticker symbol “VIR.”

IPO Quiet Period Expiry

Satsuma Pharmaceuticals Inc STSA 4.58%
SpringWorks Therapeutics Inc SWTX 5.47%
10X Genomics Inc TXG 6.92%
https://www.benzinga.com/general/biotech/19/10/14541123/the-week-ahead-in-biotech-pfenex-and-clinuvel-on-the-radar-ahead-of-fda-decisions-2-ipos-on-deck